Skip to main content
Premium Trial:

Request an Annual Quote

Huntington's Trial Discontinued

A late-stage clinical trial of a Huntington's disease treatment is being discontinued, according to Science.

Roche had been testing tominersen, an investigational antisense therapy aimed at reducing the level of mutated huntingtin protein, mHTT, among people with Huntington's disease. But the company announced that, based on a recommendation from its Independent Data Monitoring Committee, it would be stopping dosing in the trial. According to Roche, the panel made its recommendation based on tominersen's potential benefit/risk profile for study participants.

"This is very unfortunate news to deliver on the tominersen Phase III study and we know it will be especially difficult for people with Huntington's disease to hear," Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, says in a statement. The company says it plans to analyze the data from the trial and share what it has learned with the Huntington's disease community.

According to Science, the decision to stop the trial surprised its investigators, who recently said they expected it to provide results in 2022. 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.